Success Metrics

Clinical Success Rate
77.3%

Based on 17 completed trials

Completion Rate
77%(17/22)
Active Trials
2(8%)
Results Posted
100%(17 trials)
Terminated
5(21%)

Phase Distribution

Ph phase_2
11
46%
Ph phase_3
13
54%

Phase Distribution

0

Early Stage

11

Mid Stage

13

Late Stage

Phase Distribution24 total trials
Phase 2Efficacy & side effects
11(45.8%)
Phase 3Large-scale testing
13(54.2%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

77.3%

17 of 22 finished

Non-Completion Rate

22.7%

5 ended early

Currently Active

2

trials recruiting

Total Trials

24

all time

Status Distribution
Active(2)
Completed(17)
Terminated(5)

Detailed Status

Completed17
Terminated5
Recruiting2

Development Timeline

Analytics

Development Status

Total Trials
24
Active
2
Success Rate
77.3%
Most Advanced
Phase 3

Trials by Phase

Phase 211 (45.8%)
Phase 313 (54.2%)

Trials by Status

terminated521%
recruiting28%
completed1771%

Recent Activity

Clinical Trials (24)

Showing 20 of 24 trialsScroll for more
NCT07164443Phase 3

A Study of Pasritamig Versus Placebo in Late Line Metastatic Castration-resistant Prostate Cancer (mCRPC)

Recruiting
NCT06341712Phase 2

Effects of Maintenance Cabozantinib+BSC Versus BSC in Children and AYA With Osteosarcoma

Terminated
NCT07225374Phase 2

Cisplatin-Based Chemotherapy Followed by Maintenance Avelumab in UTUC

Recruiting
NCT04161885Phase 3

A Study Evaluating Safety and Efficacy of Venetoclax in Combination With Azacitidine Versus Standard of Care After Allogeneic Stem Cell Transplantation (SCT) in Participants With Acute Myeloid Leukemia (AML)

Terminated
NCT03062358Phase 3

Study of Pembrolizumab (MK-3475) or Placebo Given With Best Supportive Care in Asian Participants With Previously Treated Advanced Hepatocellular Carcinoma (MK-3475-394/KEYNOTE-394)

Completed
NCT02269280Phase 2

Phase II Decitabine (DAC) Versus Azacitidine (AZA) in Myelodysplastic Syndrome (MDS)

Completed
NCT03342404Phase 2

A Study to Determine the Efficacy and Safety of Luspatercept in Adults With Non Transfusion Dependent Beta (β)-Thalassemia

Completed
NCT02460419Phase 3

Maintenance Capecitabine Plus Best Supportive Care Versus Best Supportive Care for Metastatic Nasopharyngeal Carcinoma

Completed
NCT02562443Phase 3

Controlled Study of Rigosertib Versus Physician's Choice of Treatment in MDS Patients After Failure of an HMA

Terminated
NCT04475588Phase 2

Efficacy and Safety of Itolizumab in COVID-19 Complications

Completed
NCT02625623Phase 3

Avelumab in Third-Line Gastric Cancer (JAVELIN Gastric 300)

Completed
NCT00917384Phase 3

Study of IMC-1121B (Ramucirumab) With Best Supportive Care in Participants With Gastric Cancer and Adenocarcinoma

Completed
NCT01358734Phase 2

A Study Being Conducted at Multiple Locations to Compare Safety and Efficacy of Three Different Regimens; (1) High-Dose Lenalidomide; (2) Lenalidomide + Azacitidine; or (3) Azacitidine in Subjects ≥ 65 Years With Newly-Diagnosed Acute Myeloid Leukemia

Completed
NCT02083653Phase 2

Sym004 vs Standard of Care in Subjects With Metastatic Colorectal Cancer

Completed
NCT01024036Phase 2

A Study to Evaluate the Efficacy and Safety of CNTO328 Plus Best Supportive Care in Multicentric Castleman's Disease

Completed
NCT01412957Phase 3

Comparison of Survival Benefit of Panitumumab With Supportive Care to Best Supportive Care Alone in Patients With Metastatic Colorectal Cancer

Completed
NCT01015443Phase 3

Cancer Vaccine Study for Stage III, Unresectable, Non-small Cell Lung Cancer (NSCLC) in the Asian Population

Terminated
NCT01035229Phase 3

Global Study Looking at the Combination of RAD001 Plus Best Supportive Care (BSC) and Placebo Plus BSC to Treat Patients With Advanced Hepatocellular Carcinoma.

Completed
NCT01585987Phase 2

An Efficacy Study in Gastric and Gastroesophageal Junction Cancer Comparing Ipilimumab Versus Standard of Care Immediately Following First Line Chemotherapy

Completed
NCT00157209Phase 2

Phase 2b Randomized Controlled Study of Tecemotide (L-BLP25) for Immunotherapy of NSCLC (Non-Small Cell Lung Cancer)

Completed

Drug Details

Intervention Type
DRUG
Total Trials
24